Treatment News : Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment - by David Evans

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 22, 2009

Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment

by David Evans

People who took a regimen including efavirenz (found in Sustiva and Atripla) for five days each week, with two-days off over the weekend, had similar viral load reductions and side effects as people who took their regimen continuously. What’s more, people on the on-off approach reported universally that they preferred intermittent therapy to continuous therapy. Cal Cohen, MD, from the Community Research Initiative (CRI) in Boston, presented the study at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.

People with HIV have long sought the opportunity to take their antiretroviral therapy less often, but results of treatment interruption trials have been mixed, at least for longer interruptions. The researchers at CRI set out to determine whether short, two-day, weekly treatment interruptions may be safe and effective. Their study, Five-days-On, Two-days Off (FOTO), enrolled 60 HIV-positive patients who were new to HIV treatment. Half were randomized to the intermittent treatment arm, and half to the continuous therapy arm.

Cohen previously presented 24-week data from the study in November 2008, at the Ninth International Congress on Drug Therapy in HIV Infection in Glasgow. That early look at the data was promising, and the 48-week data have continued in the same vein.

Ten people dropped out of the study before the end of the 48 weeks. All had a viral load of less than 50 copies at the time they discontinued. Reasons for discontinuation included loss to follow-up, withdrawal of consent to participate and one pregnancy.

At the 24-week time point, 100 percent of the patients in the interruption arm had a viral load of less than 50 copies, compared with 86 percent in the continuous therapy arm. After 24 weeks, all of the patients in the continuous therapy arm switched to intermittent therapy. At 48 weeks, 90 percent of those participants had a viral load less than 50 copies.

Adherence in neither group was superior at 24 weeks. Eight percent of people in the intermittent therapy arm reported at week 24 that they took an extra day off treatment at least once during the first 24 weeks. Eleven percent in the continuous therapy arm reported missing a dose. Yet despite the extra doses missed, people in the intermittent treatment arm did remarkably well.

Though the study is small and larger studies will be needed to confirm the efficacy and safety of this strategy, people in the study liked it quite a bit. Those who’d been on the continuous therapy arm and then switched to intermittent treatment told researchers that they much preferred taking intermittent treatment. The authors also note that the total cost of treating a patient on intermittent therapy is 28 percent less than patients on continuous therapy.

Search: Efavirenz, Sustiva, Atripla, FOTO, intermittent treatment, treatment interruption, Cal Cohen

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.